Novel therapeutic agents for B-cell lymphoma: Developing rational combinations

Blood

Volumn 117, Issue 5, 2011, Pages 1453-1462

  Reeder, Craig B ^a   Ansell, Stephen M ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ACETYLSALICYLIC ACID; BENDAMUSTINE; BORTEZOMIB; CAL 101; CARFILZOMIB; CELL SURFACE RECEPTOR; DENILEUKIN DIFTITOX; ENZASTAURIN; ENZYME INHIBITOR; EVEROLIMUS; FOSTAMATINIB; LENALIDOMIDE; MOCETINOSTAT; OBATOCLAX; PANOBINOSTAT; PCI 32765; PERIFOSINE; PHOSPHOTRANSFERASE INHIBITOR; POMALIDOMIDE; PRALATREXATE; PROTEIN KINASE SYK INHIBITOR; ROMIDEPSIN; SB 1518; SORAFENIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALBUMIN BLOOD LEVEL; ANEMIA; ANGIOGENESIS; B CELL LYMPHOMA; B CELL NONHODGKIN LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CELL; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC LYMPHOCYTIC LYMPHOMA; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DIARRHEA; DNA DAMAGE; DNA SYNTHESIS; DRUG ACTIVITY; DRUG TARGETING; EDEMA; ENZYME INHIBITION; FATIGUE; FOLLICULAR LYMPHOMA; HELPER CELL; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; KIDNEY CANCER; LEUKOPENIA; LIVER CANCER; LYMPHOCYTOMA; LYMPHOMA; MACROPHAGE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOSIS; TUMOR MICROENVIRONMENT; VASCULAR LEAK SYNDROME;

EID: 79551623391     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-255067     Document Type: Review

References (89)

1. Lenz G, Staudt ML. Aggressive lymphomas. N Engl J Med. 2010;362:1417-1429.
2. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001;19(3):720-726. (Pubitemid 32119086)
3. Alvaro T, Lejeune M, Salvado M-T, et al: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350-5357. (Pubitemid 46623165)
4. Carreras J, Lopez-Guillermo A, Roncador G, et al: High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27:1470-1476.
5. Lee AM, Clear AJ, Calaminici M, et al: Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24:5052-5059.
6. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2006;66(20):10145-10152.
7. Alvaro T, Lejeune M, Camacho FI, et al: The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006;91:1605-1612.
8. Shiozawa E, Yamochi-Onizuka T, Yamochi T, et al: Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: Immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract. 2003;199:293-302. (Pubitemid 36939580)
9. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
10. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson K. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma. 2008;49(7):1238-1245. (Pubitemid 352015786)
11. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer P, Stirling D. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006;30:849-858. (Pubitemid 43816707)
12. Verhelle D, Corral L, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B Cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67(2):746-755.
13. Zhu D, Corral LG, Fleming Y, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 2008;57:1849-1859.
14. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med. 1996;2:506-515. (Pubitemid 26271704)
15. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(p) and CD8(p) T cells. Clin Exp Immunol. 2002;130:75-84.
16. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952-4957.
17. Witzig TE, Vose JM, Zinzani PL, et al. Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003) [abstract]. Blood. 2009;114:Abstract 1676.
18. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344-349.
19. Reeder CB, Witzig TE, Zinzani PL, et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003) [abstract]. J Clin Oncol. 2009;27:15s. Abstract 8569.
20. Witzig TE, Vose JM, Moore TD, et al. Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood. 2007;110:2560.
21. Witzig TE, Vose JM, Justice G, et al. Lenalidomide oral monotherapy in relapsed/refractory small lymphocytic non-Hodgkin's lymphoma [abstract]. J Clin Oncol. 2008;26(suppl): Abstract 8573.
22. Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:4095-4102.
23. Kuzel TM, Li S, Eklund J, Foss F, et al. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk Lymphoma. 2007;48(12):2397-2402. (Pubitemid 350253471)
24. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
25. Young R, Hardy I, Clark R, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood. 2009;113:2508-2516.
26. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008;111:2230-2237. (Pubitemid 351451430)
27. Friedberg J, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
28. Advani R, Sharman JP, Smith SM, et al. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study [abstract]. J Clin Oncol. 2020;28(suppl):15s. Abstract 8012.
29. Younes A, Fanale M, McLaughlin P, et al. Phase-I study of the novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity. Blood. 2009;114:588.
30. Furman RR, Byrd JC, Flynn IW, et al. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies [abstract]. J Clin Oncol. 2010;28(suppl):15s. Abstract 3032.
31. Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep. 2009;11:102-110.
32. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053-4062.
33. Ghobrial IM, Roccaro A, Hong, F et al. Clinical and translational studies of a phase ii trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clin Cancer Res. 2010;16(3):1033-1041.
34. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007;13(10):433-442. (Pubitemid 47570021)
35. Ghosh S, Tergaonkar V, Rothlin CV, et al. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kB activation and cell survival. Cancer Cell. 2006;10:215-226.
36. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356.
37. Ansell SM, Inwards DJ, Rowland KM, et al. Lowdose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113(3):508-514.
38. Smith SM, Pro B, Cisneros A, et al. Activity of single agent temsirolimus (CCI-779) in nonmantle cell non-Hodgkin lymphoma subtypes [abstract]. J Clin Oncol. 2008;26:8514.
39. Reeder CB, Gornet MK, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL) [abstract]. Blood. 2007;110: Abstract 121.
40. Johnston PB, Ansell SM, Colgan JP, et al. mTOR Inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001) [abstract]. Blood. 2007;110:2555.
41. Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1408-1414.
42. Platanias LC. Map kinase signaling pathways and hematologic malignancies, Blood. 2003;101(12):4667-4679. (Pubitemid 36857719)
43. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351:289-305.
44. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937-947.
45. Witzig TE, Maurer MJ, Johnston PB, et al. Oral tipifarnib (R115777) has single agent anti-tumor activity in patients with relapsed aggressive non-Hodgkin lymphoma (NHL): results of a phase II trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274) [abstract]. Blood. 2006;108:530.
46. Rolland D, Ribrag V, Haioun C, et al. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. Cancer Chemother Pharmacol. 2009;65(4):781-790.
47. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5(10):835-844.
48. Riihijärvi S, Koivula S, Nyman H, Rydström K, Jerkeman M, Leppä S. Prognostic impact of protein kinase C beta II expression in R-CHOPtreated diffuse large B-cell lymphoma patients. Mod Pathol. 2010;23(5):686-693.
49. Su TT, Guo B, Kawakami Y, et al. PKC-β controls Iκ B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol. 2002;3(8):780-786.
50. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98(9):2018-2026.
51. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom's macroglobulinemia. Blood. 2007;109:4964-4972.
52. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007;109(4):1669-1677.
53. Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol. 2008;19(2):247-253.
54. Schwartzberg L, Hermann RC, Flinnet IW, et al. Enzastaurin in patients with follicular lymphoma: results of a phase II study [abstract]. J Clin Oncol. 2020;28(suppl):15s. Abstract 8040.
55. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-κ B activation in multiple myeloma cells. Blood. 2009;114(5):1046-1052.
56. McConkey DJ. Bortezomib paradigm shift in myeloma. Blood. 2009;114(5):931-932.
57. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675.
58. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684.
59. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase ii study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-4874.
60. Goy A, Bernstein S, Kahl B, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520-525.
61. Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475-480.
62. O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Ca Res. 2010;16(2):719-726.
63. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269:7-17.
64. Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan- deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies [abstract]. Blood. 2008;112:958.
65. Younes A, Ong T-C, Ribrag V, et al. Efficacy of panobinostat in phase ii study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant [abstract]. Blood. 2009;114:923.
66. Crump M, Andreadis C, Assouline S, et al. Treatment of relapsed or refractory non-Hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study [abstract]. J Clin Oncol. 2008;26:8528.
67. Bociek RG, Kuruvilla JB, Pro B, et al. Isotypeselective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL) [abstract]. J Clin Oncol. 2008;26:8507.
68. Kirschbaum M, Popplewell L, Nademanee AP, et al. A Phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin's lymphoma. A California Cancer Consortium Study [abstract]. Blood. 2008;112:1564.
69. Wilson WH, O'Connor O, Czuczman MS, et al. Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies [abstract]. Blood. 2008;112:2108.
70. Roberts AW, Brown J, Seymour JF, et al. An ongoing phase 1 study of ABT-263; pharmacokinetics, safety and anti-tumor activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2008;112:3177.
71. Goy A, Ford P, Feldman T, et al. A Phase 1 trial of the Pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma [abstract]. Blood. 2007;110:2569.
72. Plosker GL, Carter NJ. Bendamustine, a review of its use in the management of indolent non-Hodgkin lymphoma. Drugs. 2008;68(18):2645-2660.
73. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27:1492-1501.
74. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase ii multicenter, single-agent study. J Clin Oncol. 2008;26:204-210.
75. Kahl B, Bartlett NL, Leonard JP, et al. Bendamustine is safe and effective in patients with rituximab-refractory, indolent b-cell non-Hodgkin lymphoma [abstract]. Blood. 2007;110:1351.
76. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol. 1998;42:313-318.
77. O'Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol. 2007;139:425-428.
78. Rummel MJ, Al-Batran SE, Kim S-Z, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
79. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
80. Rummel RJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as firstline treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase iii study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood. 2009;114:405.
81. Fowler N, McLaughlin P, Hagemeister F, et al. High Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma [abstract]. J Clin Oncol. 2010;28(suppl):7s. Abstract 8036.
82. Dang NH, Fayad L, McLaughlin P, et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007;138:502-505.
83. Ansell SM, Tang H, Kurtin P, et al. A Phase II study of temsirolimus (CCI-779) in combination with rituximab in patients with relapsed or refractory mantle cell lymphoma [abstract]. Blood. 2009;114:1665.
84. Sehn LH, Macdonald DA, Rubin SH, et al. Tolerability and efficacy of bortezomib added to CVP-R for previously untreated advanced stage follicular lymphoma: interim analysis of a phase ii study by the NCIC clinical trials group [abstract]. Blood. 2008;112:1576.
85. Leonard JP, Furman RR, Cheung YK, et al. CHOP-R+ bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL) [abstract]. J Clin Oncol. 2007;25(suppl):8031. Abstract 18S.
86. Barr PM, Fu P, Lazarus HM, et al. Phase I dose escalation study of fludarabine, bortezomib, and rituximab for relapsed/refractory indolent and mantle cell non- Hodgkin lymphoma [abstract]. J Clin Oncol. 2008;26:8553.
87. Kahl B, Chang J, Eickhoff J, et al. VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase ii study from the Wisconsin Oncology Network [abstract]. Blood. 2008;112:265.
88. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study [abstract]. Blood. 2009;114:933.
89. Friedberg JW, Vose JM, Kelly JL, et al. Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter phase ii clinical trial [abstract]. Blood. 2009;114:924.